[1] Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2015; 385:441-51.
[2] Galasso G, Schiekofer S, D'Anna C, Gioia GD, Piccolo R, Niglio T, et al. No-Reflow Phenomenon: Pathophysiology, Diagnosis, Prevention, and Treatment. A Review of the Current Literature and Future Perspectives. Angiology. 2014; 65:180-9.
[3] The Lancet. 40 years of percutaneous coronary interven-tion: Where next? Lancet. 2017; 390: 715
[4] Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001; 22:729-39.
[5] Stone GW, Peterson MA, Lansky AJ, Dangas G, Meenran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 2002; 39: 591-7
[6] Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003; 145: 42-6
[7] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
[8] Wang C, Jing Q. Non-coding RNAs as biomarkers for acute myocardial infarction. Acta Pharmacol Sin. 2018; 39: 1110-9.
[9] Jakob P, Kacprowski T, Briand-Schumacher S, Heg D, Klingenberg R, Stähli BE, et al. Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. Eur Heart J. 2017; 38:511.
[10] Emmrich S, Henke K, Hegermann J, Ochs M, Reinhardt D, Klusmann JH. miRNAs can increase the efficiency of ex vivo platelet generation. Ann Hematol. 2012; 91:1673–84.
[11] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction. Circulation. 2018;138: e618-e651.
[12] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39:119–77.
[13] Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165.
[14] Gibson CM, Murphy SA, Morrow DA, Aroesty JM, Gibbons RJ, Gourlay SG, et al. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J. 2004; 148:336–40
[15] Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55:611-22.
[16] Fung EC, Butt AN, Eastwood J, Swaminathan R, Sodi R. Circulating microRNA in cardiovascular disease. Adv Clin Chem, 2019, 91: 99-122.
[17] Karimianpour A, Maran A. Advances in coronary no-reflow phenomenon—a contemporary review. Curr Atheroscler Rep. 2018, 20: 44
[18] Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002; 99:7634–9.
[19] Chaitman B, Lim B. No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction. J Am Coll Cardiol. 2004; 44:313–5.
[20] Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 46:284–90.
[21] Niccoli G, Celestini A, Calvieri C. Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. Eur Heart J Acute Cardiovasc Care. 2013; 2:379–88.
[22] Huczek Z, Filipiak KJ, Kochman J, Piatkowski R, Grabowski M, Roik M, et al. Baseline platelet reactivity in acute myocardial infarction treated with prymari angioplasty- influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J. 2007; 154:62–70
[23] Aurigemma C, Scalone G, Tomai F, Altamura L, De Persio G, Stazi A, et al. Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications. Thromb Haemost. 2014; 111:122-30.
[24] Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J. 2008; 29:1843-50.
[25] Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A.2006; 103:5078-83
[26] Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res.2009; 37: D105-10.
[27] Martin J, Bath PMW, Burr ML. Increased platelet size following myocardial infarction is associated with subsequent death and nonfatal reinfarction. Lancet. 1991; 338:1409–11